Navigation Links
GlaxoSmithKline and Genmab Present Positive Phase II Results With,ofatumumab in Patients With Rheumatoid Arthritis (RA)

New Data to be Presented at the European League Against Rheumatism (EULAR) Congress Demonstrates the Potential Benefit of ofatumumab in Patients With Rheumatoid Arthritis

LONDON, England; PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, June 15, 2007 /PRNewswire-FirstCall/ -- GlaxoSmithKline (GSK) and Genmab A/S (CSE: GEN) announced today positive primary efficacy data (evaluated at 24 Weeks) to be presented at EULAR 2007, the Annual European Congress of Rheumatology (abstract number: OPO232) from a Phase II study of ofatumumab (HuMax-CD20(R)) in patients with rheumatoid arthritis (RA). Ofatumumab is being co-developed under a worldwide agreement between GlaxoSmithKline and Genmab.

A total of 225 patients with active RA who have previously failed one or more disease-modifying anti-rheumatic drugs (DMARDs) were enrolled into this double-blind placebo controlled study to evaluate the safety and efficacy of ofatumumab. Patients within the study were randomized into one of four treatment groups (300 mg, 700 mg or 1000 mg ofatumumab or placebo) and assessed based on their of Rheumatology (ACR) and EULAR responses at 24 weeks. Continuation of current stable doses of methotrexate and low dose corticosteroids were permitted.

In the intention-to-treat study population, comprising 224 patients, ACR20 was achieved by 46% of all patients receiving ofatumumab, ACR50 achieved by 24% and ACR70 achieved by 6% of ofatumumab patients compared to 15%, 5% and 0% in the placebo group. Evaluated by dose groups, an ACR20 response was obtained by 41% (p=0.002), 49% (p<0.001) and 46% (p<0.001) of patients receiving 300 mg, 700 mg and 1000 mg of ofatumumab. An ACR50 response was obtained by 19%, 26% and 26% of patients receiving the varying doses of ofatumumab, with 9%, 4% and 6% obtaining an ACR70 response. These scores indicate a 20%, 50% or 70% improvement respectively in the number of swollen and tender joints, as w
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
2. New Data on Genmab and GlaxoSmithKlines Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR
3. Genmabs HuMax-EGFr Shows Broad Potential in Cancer Treatment
4. The Past, Present and Future of HLA Typing
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
10. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
11. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/17/2014)... , September 17, 2014 ... GRC 17536, has shown positive data in a Phase ... diabetic neuropathy , Glenmark Pharmaceuticals ... Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown ... controlled, multi-centre, proof of concept study conducted on 138 ...
(Date:9/17/2014)...  Members of the physician IT team at ... today that the enterprise is working with ... capabilities and provide immediate cluster fail over in ... the Dicom Systems enterprise imaging solutions will be ... more effectively deliver the right images to the ...
(Date:9/17/2014)... 2014 An analysis done by the CVS ... (sofosbuvir), a new and expensive treatment for Hepatitis C ... last several months (May through August 2014) there has ... utilization. This suggests another surge of patients will begin ... similar efficacy and shorter duration are introduced in the ...
Breaking Medicine Technology:Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4
... Event for Congressional Members and Staff Will Focus on Advances ... Research and Treatment of Lung Cancer in ... CTIC; MTAX:), along with the Society for Women,s Health,Research, the ... "Lung Cancer: Being Female Matters to Research," on,Capitol Hill to ...
... in cSSSI, CAMBRIDGE, Mass., Sept. 13 ... Phase 2 trial,investigating the safety and efficacy of ... of Complicated Skin and Skin Structure,Infections (cSSSI), or ... positive infections. This Phase 2 study is ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 2Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 3Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study 2Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study 3
(Date:9/17/2014)... like the ideas of a science fiction writer, ... exciting new approach to imaging local and metastatic ... cancer, scientists at Virginia Commonwealth University Massey Cancer ... Hopkins Medical Institutions have provided proof-of-principle of a ... ability to see tumors that have metastasized to ...
(Date:9/17/2014)... 17, 2014 Catalent Pharma Solutions, ... and development solutions for drugs, biologics and consumer ... an integrated service and technology offer based on ... from the company’s 450,000 sq. ft. Kansas City, ... to integrate optimal formulation, development, analytical expertise, scale ...
(Date:9/17/2014)... 2014 (HealthDay News) -- Positive messages about the health ... the habit, a new study suggests. Although smokers ... "loss-framed" messages about the harmful effects of smoking, researchers ... want benefit more from "gain-framed," or positive, messages about ... concluded that using a mix of both types of ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 Smart ... Editor’s Picks by Progressive Grocer, a leading trade magazine ... was awarded for originality and flavor, among other attributes. ... as an Editor’s Pick in the September print issue ... Grocer website. , The pizza won based on its ...
Breaking Medicine News(10 mins):Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2
... A new technology called the Cone beam computerized tomography ... to diagnose complicated oral problems.// ,J. Martin ... at the Case Western Reserve University School of Dental ... department of dental health and biological sciences at the ...
... two protein complexes which is found to protect cell ... number of chromosomes leading to cell instability which leads ... research team from Mayo Clinic have found that the ... which maintains the euploidy state in the cell and ...
... The waiting times at Ontario’s hospitals are getting longer, according ... revealed by Elizabeth Witmer, the Conservative health critic.// The waiting ... and September 2005 for cancer surgery, while it rose from ... time increased to 22 days for cardiac surgeries, while in ...
... genetic code is reported to have been cracked by ... faster diagnosis and treatment of the ailment which causes ... Jewish General Hospital’s Dasval. The strain has caused infections ... The search can now commence for the other antibiotic ...
... Institute (SERI) found that increasing the contrast of details ... the visually impaired. // ,The U.S. study provides ... help millions suffering eye diseases. People who may benefit ... degeneration, diabetic retinopathy and other causes of low vision. ...
... National Laboratories, Gerry Yonas was the first to visualize a need ... the development of the BiNational Sustainability Laboratory (BNSL), which extends over ... mainly augment the border security force and deal with terrorism ... ,The monetary inputs for the lab come from USA, ...
Cached Medicine News:Health News:New Computerized Imaging Systems Help In Better Dental Treatment Planning 2Health News:Visually impaired prefer specially enhanced TV 2Health News:Visually impaired prefer specially enhanced TV 3
Cold light source single outlet....
Cold light source triple outlet....
Cold light source single outlet....
... is a state of the ... source with an integrated intensity ... to connect optical fiber light ... itself from all others by ...
Medicine Products: